Skip to main content

Marta Martínez Vicente

I am senior researcher at the VHIR, I’m a Principal Investigator at the Neurodegenerative Diseases Group and I head the Autophagy and Lysosomal Dysfunction lab.

Institutions of which they are part

Main researcher
Neurodegenerative Diseases
Vall Hebron Institut de Recerca

Marta Martínez Vicente

Institutions of which they are part

Main researcher
Neurodegenerative Diseases
Vall Hebron Institut de Recerca

I am senior researcher at the VHIR, I’m a Principal Investigator at the Neurodegenerative Diseases Group and I head the Autophagy and Lysosomal Dysfunction lab.

I obtained a degree in Chemistry/Biochemistry and a PhD in Biochemistry by the University of Valencia. From 2004 to 2008, I worked as a postdoctoral researcher at the laboratory of Dr. Ana Maria Cuervo at the Albert Einstein College of Medicine (New York, USA), focusing on the role of autophagy in neurodegenerative diseases and aging.
I obtained in 2010 a tenure-track position as Miguel Servet I in the Neurodegenerative Diseases Group of the VHIR and since January 2016 I became VHIR Senior Researcher (Miguel Servet II-A).
Currently, the efforts of my team are devoted to study the role of autophagy in neurodegeneration. Alterations in the autophagy process have been associated with neurodegenerative diseases including Parkinson’s, Huntington’s and Alzheimer’s disease and has been shown to be one of the main causes that contribute to neuronal death in these pathologies. Our efforts are currently directed to: 1) Study the role of the autophagic and lysosomal dysfunction in Parkinson’s disease; 2) Development of new therapies for Parkinson’s disease based in the restoration of lysosomal glucocerebrosidase (GBA) activity; 4) Unravel the link between Parkinson and lysosomal storage diseases, 4) Characterize the defective lysosomal-mediated turnover of mitochondria and aggregates in Huntington’s disease and its contribution to neurodegeneration.
I’ve been able to turn my group into a reference group in the study of autophagy in neurodegeneration and aging. This position is endorsed by our publications, projects, dissemination activities and participation in scientific organizations. Bibliographic parameters: h-index: 31. Citations: >12.000, Publications: 49 scientific articles and mean impact factor/publication in the last 6 years = 10.6. I’ve been PI of several research projects funded by public agencies like ISCIII and MINECO as well as private entities as the Michael J. Fox Foundation, the Silverstein foundation and the BBVA Foundation, in addition I have also been PI in several collaboration agreements with private biotech companies.
I’m member of the Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), member and part of the management committee (board member) of the Spanish Autophagy Network (SEAFAGIA), member and part of the management committee of the European COST TRANSAUTOPHGAY network, member and part of the Scientific Advice Committee of the Women in Autophagy (WIA), member of the Spanish Society of Biochemistry and Molecular Biology (SEBBEM), and member of the Association of Women Researcher and Technologists (AMIT). As member of theses scientific societies I participated in the organization of national and international scientific conferences and I am member of the Editorial Board of Cells (ISSN 2073-440). I am in possession of the accreditation of Associate Professor/Researcher by the Agència per a Qualitat del Sistema Universitari de Catalunya (AQU).

Projects

Altered autophagy in Huntington's disease

IP: Marta Martínez Vicente
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 34836.65
Reference: CP09/00184
Duration: 01/01/2010 - 31/12/2013

Grup de Recerca en Malalties Neurodegeneratives

IP: Miquel Vila Bover
Collaborators: Marta Martínez Vicente, Jordi Bove Badell, Thais Cuadros Arasa, Annabelle Parent
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 41600
Reference: 2009 SGR 664
Duration: 01/01/2010 - 30/04/2014

Related news

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Vall d'Hebron has participated in a phase III clinical trial which confirmed the efficacy and safety of subcutaneous infusion of levodopa therapy.

This initiative is part of a pioneering study that seeks to assess how the relationship between different age groups can influence the quality of life and mental health of patients.

Related professionals

Clara Serra Juhe

Clara Serra Juhe

Postdoctoral researcher
Genetics Medicine
Read more
Bárbara Bolonci

Bárbara Bolonci

Read more
Eddie Pradas Gracia

Eddie Pradas Gracia

Research technician
Neurodegenerative Diseases
Read more
Maria Isabel Borja Garcia

Maria Isabel Borja Garcia

Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.